Alcyone Therapeutics Inc.
Alcyone Lifesciences, Inc.
- UEI
- H5XUM7B92JC7
- CAGE
- 7FK52
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Website
- alcyonetx.com
- Founded
- 2010
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $115,998 |
| FY2024 | $495,000 |
| FY2023 | $425,000 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| The proposed research plan builds on our groups ongoing research to quantify ophthalmic and intracranial changes in… | Shared Services Center | $1,265,998 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| The proposed research plan builds on our groups ongoing research to quantify ophthalmic and intracranial changes in… | Shared Services Center | $1,265,998 |
Similar vendors
About the company
Alcyone Therapeutics Inc. is a biotechnology company developing precision therapies for neurological disorders with high unmet medical needs. The company is pioneering next generation precision gene-based therapies for complicated disorders of the central nervous system. Alcyone Therapeutics Inc. provides research services to the federal government through contract and grant awards.
Alcyone Therapeutics Inc. has been awarded a federal contract by the National Aeronautics and Space Administration (NASA) to conduct research on quantifying ophthalmic and intracranial changes in long-duration space flight astronauts using novel non-invasive magnetic resonance imaging (MRI) protocols and post-processing. The $1,265,998.00 contract, which does not have a set-aside designation, is for research and is set to be completed by December 7, 2024. As a sub-contractor, Alcyone Therapeutics Inc. will send MRI sequences to Dr. Martin to conduct ocular MRI analyses using techniques that have been previously used on other astronauts and bedrest MRI sequences.
Alcyone Therapeutics Inc. has been awarded a $900,000.00 federal project grant by the National Aeronautics and Space Administration Shared Services Center for research related to quantifying ophthalmic and intracranial changes in long-duration space flight astronauts using novel non-invasive magnetic resonance imaging (MRI) protocols and post-processing. The grant, which is set to be completed by December 7, 2024, builds on the company's ongoing research in this area and aligns with NASA's broader efforts to understand the physiological impacts of long-duration spaceflight.
Quick answers
Is Alcyone Therapeutics Inc. registered in SAM.gov?
Alcyone Therapeutics Inc.'s SAM.gov registration expired on January 24, 2026.
How much has Alcyone Therapeutics Inc. received in federal contracts?
Federal contracts obligated $115,998 to Alcyone Therapeutics Inc. in fiscal year 2025 and $1,035,998 in fiscal years 2023 through 2027.
What is Alcyone Therapeutics Inc.'s most recent federal award?
Alcyone Therapeutics Inc.'s most recent federal contract award is The proposed research plan builds on our groups ongoing research to quantify ophthalmic and intracranial changes in… (80NSSC22K0023), from Shared Services Center, on December 8, 2021.
On GovTribe
See Alcyone Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors